Clinical Trials Currently Conducted at NJRetina

Age-Related Macular Degeneration

GALLEGO-GR40973 (Sponsor: Roche/Genentech)
2019-present


NCT Number: NCT03972709

A Phase II, Multi-Center, Randomized, Single-Masked, Sham Injection Controlled Study of the Safety, Tolerability, and Evidence of Activity of Intravitreal Injection of R7171009 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

For more information, click here.

 

Age-Related Macular Degeneration

SPIAM-202 (Sponsor: Stealth)
2019-present


NCT Number: NCT03891875
A Phase II, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Evaluate the Safety, Efficacy and Pharmakinetics of Subcutaneous Injections of Elamipretide in Subjects with Age-Related Macular Degeneration with Geographic Atrophy

For more information, click here.

 

Age-Related Macular Degeneration

APL2-304 (Sponsor: Apellis)
2018-present


NCT Number: NCT03525613

A Phase III, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

For more information, click here.

 

Age-Related Macular Degeneration

Tenaya GR40306 (Sponsor: Roche/Genentech)
2019-present


NCT Number: NCT03823287

A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate R06867461 in Patients with Neovascular Age-Related Macular Degeneration

For more information, click here.

 

Diabetic Retinopathy

Robin (Sponsor: Boehringer Ingelheim)
2017-present


NCT Number: NCT03238963

A randomized, double-masked, placebo-controlled exploratory study to evaluate safety, tolerability, pharmacodynamics and pharmacokinetics of orally administered BI 1467335 for 12 weeks with a 12 week follow up period in patients with nonproliferative diabetic retinopathy without center-involved diabetic macular edema

For more information, click here.

 

Age-Related Macular Degeneration

Panda KHB-1802 (Sponsor: Chengdu)
2018-present


NCT Number: NCT03630952

A Phase III, Multi-Center, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age-Related Macular Degeneration

For more information, click here.

 

Diabetic Macular Edema

Yosemite- GR40349 (Sponsor: Roche/Genentech)
2018-present


NCT Number: NCT03622580

A Phase III, Multi-Center, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of RO6867461 in Patients with Diabetic Macular Edema

For more information, click here.

 

Age-Related Macular Degeneration

Archway Ranibizumab GR40548 (Sponsor: Roche/Genentech)
2018-present


NCT Number: NCT03677934

A Phase III, Multi-Center, Randomized, Visual Assessor-Masked, Active-Comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System with Ranibizumab in Patients with NeoVascular Age-Related Macular Degeneration

For more information, click here.

 

Age-Related Macular Degeneration

Candela (Sponsor: Roche/Genentech)
2019-present


NCT Number: NCT04126317

A Randomized, Single-Masked, Active-Controlled Phase 2 Study of the Safety, Tolerability, and Efficacy of Repeated Doses of High-Dose Aflibercept in Patients with Neovascular Age-Related Macular Degeneration

For more information, click here.

 

Kodiak Sciences Inc., KS301P107 DAYLIGHT

A Prospective, Randomized, Double-masked, Active
Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to
Evaluate the Efficacy and Safety of Intravitreal KSI-301
Compared with Intravitreal Aflibercept in Participants with
Neovascular (Wet) Age-related Macular Degeneration (wAMD)

 

Kodiak Sciences Inc., KS301P103 BEACON

A Prospective, Randomized, Double-masked, Active
Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to
Evaluate the Efficacy and Safety of Intravitreal KSI-301
Compared with Intravitreal Aflibercept in Participants with
Visual Impairment Due to Treatment-naïve Macular Edema
Secondary to Retinal Vein Occlusion (RVO)

 

Kodiak Sciences Inc., KS301P104 GLEAM

A Prospective, Randomized, Double-masked, Active
Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to
Evaluate the Efficacy and Safety of Intravitreal KSI-301
Compared with Intravitreal Aflibercept in Participants with
Visual Impairment Secondary to Treatment-naïve Diabetic
Macular Edema (DME)

 

REGENXBIO Inc., RGX-314-2202 ALTITUDE

A Phase 2, Randomized, Dose-escalation, Observation-controlled
Study to Evaluate the Efficacy, Safety, and Tolerability of
RGX-314 Gene Therapy Delivered via a Single Suprachoroidal
Space (SCS) Injection in Participants with Diabetic Retinopathy
(DR) Without Center Involved-Diabetic Macular Edema (CI-DME) (ALTITUDE)

 

Opthea OPT-302-1005 COAST

A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate
the Efficacy and Safety of Intravitreal OPT-302 in Combination with
Aflibercept, Compared with Aflibercept Alone, in Participants with
Neovascular Age-related Macular Degeneration (nAMD)

 

Opthea OPT-302-1005 SHORE

A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the
Efficacy and Safety of Intravitreal OPT-302 in Combination with Ranibizumab,
Compared with Ranibizumab Alone, in Participants with Neovascular Age-related
Macular Degeneration (nAMD)

 

F. Hoffmann-La Roche Ltd, GR41984 BALATON

A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator Controlled
Study To Evaluate Theefficacy And Safety Of Faricimab Inpatients With Macular Edema Secondary
To Branch Retinal Vein Occlusion

Questions?
Contact us today! We’re here to help!

Loading ...

©All Rights Reserved. NJRetina 2021